anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multiple binding sites for the transcription factors MAZ and Sp1 within the adenovirus type 5 major late promoter have been identified by DNase I protection studies. In the proximal region of the promoter, both MAZ and Sp1 interact with GC-rich sequences flanking the TATA box. Two MAZ binding sites are centered at -18 and -36 relative to the transcriptional initiation site. Sp1 bound only to the -18 GC-rich sequence. Several sites of interaction were also evident in the distal region of the promoter. Both MAZ and Sp1 interacted with a sequence centered at -166, and MAZ bound weakly to an additional site centered at -130. Over expression of MAZ or Sp1 activated expression from the major late promoter in transient expression assays. Mutational analysis of the GC-rich sequences in the major late promoter suggested that a primary target of MAZ activation is the GC rich sequences flanking the TATA sequence, whereas Sp1 requires the distal GC-rich sequence elements to stimulate gene expression. This activation is enhanced by the adenovirus E1A protein, and evidence for interaction between E1A and both transcription factors was obtained using an immunoprecipitation assay. Activation by MAZ and Sp1 also was observed in transfection studies using the complete adenovirus type 5 genome as the target. Increased levels of late mRNA from both the L1 and L5 regions were observed when MAZ or Sp1 expression plasmids were transfected with viral DNA. Unexpectedly, activation of the major late promoter by MAZ and Sp1 was detected irrespective of whether the viral DNA could replicate.
Standard of care PT services to included 3 to 5 therapy sessions per week, each session averaging between 20 to 50 minutes, delivered throughout the hospitalization. No specific instructions will be given to therapists providing standard of care PT, except that they cannot implement error augmentation training. Generally, standard of care PT during the initial hospitalization following acute stroke is provided with targeted patient-specific goals and typically primarily focuses on mobility and gait training. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
PURPOSE:To produce easily a linear pattern which functions as a key word which associates the features of information to be retrieved by tracing a read picture. CONSTITUTION:The original picture data forming the information to be retrieved is read by an IR5 under the control of a central processing unit CPU1 and stored to a large capacity file device EF6. Various types of indications and numeric/character data are applied to the CPU1 from a console TM2. In other words, the TW2 delivers a request to display the original picture to a display device CRT3. The feature elements of the original picture are pointed by a pointing device PD4 cnsisting of a digitizer, etc. Then a linear pattern is supplied. In a retrieval mode a linear pattern table is read out of the EF6 and displayed to the CRT3 when necessary in relation to the numeric/character data. Then an operator selects the desired associative one of linear patterns displayed on the CRT3 by the PD4.
Nonalcoholic fatty liver disease (NAFLD) is one of the common causes of chronic liver disease in the world. The problem of NAFLD had become increasingly prominent. However, its pathogenesis is still indistinct. As we all know, NAFLD begins with the accumulation of triglyceride (TG), leading to fatty degeneration, inflammation and other liver tissues damage. Notably, structure of nucleoporin 85 (NUP85) is related to lipid metabolism and inflammation of liver diseases. In this study, the results of researches indicated that NUP85 played a critical role in NAFLD. Firstly, the expression level of NUP85 in methionine-choline-deficient (MCD)-induced mice increased distinctly, as well as the levels of fat disorder and inflammation. On the contrary, knockdown of NUP85 had the opposite effects. In vitro, AML-12 cells were stimulated with 2 mm free fatty acids (FFA) for 24 h. Results also proved that NUP85 significantly increased in model group, and increased lipid accumulation and inflammation level. Besides, NUP85 protein could interact with C-C motif chemokine receptor 2 (CCR2). Furthermore, when NUP85 protein expressed at an extremely low level, the expression level of CCR2 protein also decreased, accompanied with an inhibition of phosphorylation of phosphoinositol-3 kinase (PI3K)-protein kinase B (AKT) signaling pathway. What is more, trans isomer (ISRIB), a targeted inhibitor of NUP85, could alleviate NAFLD. In summary, our findings suggested that NUP85 functions as an important regulator in NAFLD through modulation of CCR2.
The invention relates to a bifidobacterium colonic-dissolving soft capsule and a preparation method thereof. The soft capsule comprises contents and a gelatine capsule shell, wherein the capsule shell of the soft capsule is treated to have colonic solubility. The contents in the soft capsule are a stable suspension prepared from freeze-dried bifidobacterium powder, plant oil, a suspending aid and a wetting agent through uniform mixing and stirring. Additionally, the capsule shell of the soft capsule has the colonic solubility due to the fact that the soft capsule is dipped in formaldehyde. The freeze-dried bifidobacterium powder soft capsule with the plant oil as a carrier is encapsulated, has colonic solubility and good stability, is convenient to transport and store and has a longer guarantee period; bifidobacterium and the plant oil act on the colon together, the disordered intestinal flora is improved, bowel relaxing efficacy is realized, and suffering of people from constipation is eliminated. The bifidobacterium colonic-dissolving soft capsule and the preparation method thereof are used for the field of preparation of microbial ecological agents.
The present disclosure provides a system and method for image data acquisition. The method may include acquiring physiological data of a subject. The physiological data may correspond to a motion of the subject over time. The method may include obtaining a trained machine learning model configured to detect feature data represented in the physiological data. The method may include determining, based on the physiological data, an output result of the trained machine learning model that is generated based on the feature data. The method may include acquiring, based on the output result, image data of the subject using an imaging device.
Estrogens are a group of hormones that play an important role in normal sexual and reproductive development in women. Estrogens serve many functions in the body. They stimulate oocyte maturation and endometrial growth, decrease bone resorption, initiate the development of secondary sex characteristics, maintain reproductive organs and glands, and affect the activity of the central nervous system. At menopause, the decrease in estrogen concentrations is often accompanied by vascular instability (hot flushes and night sweats), a rise in the incidence of heart disease, and an increasing rate of bone loss. Estrogen is available as an oral drug, a transdermal patch, or as a gel or lotion. Transdermal estrogen is preferable as compared to oral, since it avoids the first-pass metabolism in the liver. Since release of the WHI findings, current treatment recommendations are for the lowest effective dose for the shortest period of time to treat postmenopausal symptoms.

Comparison: Three doses of a transdermal estradiol gel as compared to placebo for the treatment of vasomotor and vulvovaginal atrophy symptoms in postmenopausal women.
The present invention relates generally to a method for detecting an aberrant cell, and more particularly an apoptotic cell, in a subject or in a biological sample from said subject, and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting an apoptotic cell by detecting the presence of extranuclear nuclear molecules, in particular La, or a relative increase in extranuclear nuclear molecule levels. The present invention further provides a method for diagnosing or monitoring conditions characterized by aberrant, unwanted or otherwise inappropriate cellular apoptosis in a subject or in a biological sample from said subject by screening for up-regulation of extranuclear nuclear molecule levels in a cell or group of cells. The present invention provides diagnostic agents useful for detecting these molecules. Such diagnostic agents include immunointeractive molecules, such as antibodies.
The commercial bacteriophage preparation,PreforPro, is often found as an ingredient in commercial probiotcs, so the goal of the current study is to determine if PreforPro consumption concurrent with probiotic usage improves probiotic survival and activity. A secondary goal of this study is to assess various physiologic parameters to determine whether consumption of PreforPro with a probiotic offers any health benefits beyond those of consuming a probiotic alone. The investigators will examine whether consumption of the PreforPro product increases detectable numbers of co-consumed probiotics and improves parameters in clinical outcomes related to glucose and lipid metabolism, cardiovascular function, inflammation of the intestines, or physical symptoms of gastrointestinal distress.

To accomplish these research goals, the investigators will be seeking 200 male and female volunteers between 18-65 years old with BMI scores of 22 to 34.9. Recruitment will be by referral from local practitioners, email recruitment, and through word-of-mouth. Eligibility will be determined at the Colorado State University Food and Nutrition Clinical Research lab by a screening questionnaire and interview/assessment by the clinical coordinator. After securing consent, eligibility will be confirmed by taking anthropometric measures and participants falling within the BMI range will randomly be assigned to 1 of 3 treatment groups: (1) PreforPro+Bifidobacterium probiotic, (2) Bifidobacterium probiotic alone, or (3) placebo. Participants will consume the provided capsules daily for a period of four (4) weeks. Participants will be asked to visit the clinic at Visit 1 (Day 0) to pick up their supply of capsules and undergo sample collections (blood and stool) and analysis procedures, including weight/height, blood pressure, endothelial function analysis, gastrointestinal symptom screening, and blood and stool sample collection. At the end of the 4 week treatment period, all analyses will be repeated. This means that participants will undergo screening (either in person or by phone) and make a total of two (2) clinic visits during the study (baseline, and final visit). Participants will additionally be asked to complete two 24 hour dietary recalls prior to each clinic visit and track bowel movements using the Bristol Stool Scale throughout the study treatment period. All blood samples will be collected at Colorado State University by trained personnel. Fecal sample collection will be performed by the study participant with collection materials provided.
Cardiovascular disease (CVD) and stroke are the leading causes of mortality in the United States, accounting for more than 38% of all deaths. Elevated total- and LDL- cholesterol, number of total and small dense LDL particles, triacylglycerols, and low HDL-C are established independent risk factors for the development of CVD. Additional novel blood lipid markers used as risk factors for CVD include, increased plasma concentration of remnant like particle-cholesterol (RLP-C), decreased ratio between plasma eicosapentaenoic acid (EPA) and arachidonic acd (AA), and decreased omega-3 index (sum of EPA and DHA as a percentage of total fatty acid content) of the red blood cells.

Diets rich in omega-3 fatty acids have been shown to be cardio-protective; these diets decreased inflammation, platelet aggregation, cardiac arrhythmias, triglycerides, number of total LDL and small dense LDL particles, and increased omega-3 index, endothelial relaxation and atherosclerotic plaque stability. Most of the earlier studies regarding the effects of long chain n-3 PUFA on blood lipids were conducted with fish oils which contain a mixture of EPA and DHA. Recently a number of studies have been conducted with EPA and DHA individually. Results from studies with individual fatty acids show that EPA and DHA have similar effects on some of the lipid parameters, but they are assimilated to a different concentration in tissues and have different effects on lipoprotein particle size, heart rate and blood pressure. The main purpose of this study is to examine the effects of DHA supplementation on the above three risk factors.
Subjects who meet the inclusion/exclusion criteria for the trial will be invited to participate in the trial. Subjects will be asked to sign a consent and complete screening survey. At the onset on an episode of the subject will start a symptom diary and completed and rate the symptoms using a 4-point Likert scale for each symptom. The participant will take 2 capsules per indigestion and heartburn episode. With a max of 6 capsules per day. • After taking the test product, the participant will complete a 4-point Likert scale assessment for each symptom at 15 minutes, 30 minutes, and 1 hour after taking the test product.
The purpose of this study is to test the validity of the Weekly Calendar Planning Activity (WCPA), a test of functional cognition in persons with acquired brain injury. We will formally examine the utility, baseline profile and validity of the WCPA with adults ages 21 and above with acquired brain injury for both the WCPA 17 and WCPA 10 versions. The Weekly Calendar Planning Activity (WCPA) is a performance-based Cognitive Instrumental activities of daily living (C-IADL) task that requires working memory, planning, shifting, inhibition, and self-monitoring. The WCPA requires the examinee to input a series of 10 appointments, into a mock weekly calendar/schedule while following multiple rules, managing appointment conflicts, ignoring distracting questions by the examiner and keeping track of time. The WCPA is used routinely by occupational therapists for those with acquired brain injury, during their stay on the inpatient rehabilitation unit, prior to discharge as a measure of IADL. Persons who are currently receiving occupational therapy and would typically be given the WCPA within the course of routine occupational therapy, will be asked for permission to include their results within a database for the project. Persons who are alert, oriented x3, able to attend for at least 10 minutes, are able to read and write legibly in English would typically be administered the WCPA. Potential participants will be identified by their primary therapist. If the person does not provide consent, the WCPA will be administered as part of usual care but the results will not be included within the project.
Bexarotene gel, 1% should be initially applied once every other day for the first week. The application frequency should be increased at weekly intervals to once daily, then twice daily, then three times daily and finally four times daily according to individual lesion tolerance. Generally, patients were able to maintain a dosing frequency of two to four times per day. Most responses were seen at dosing frequencies of two times per day and higher. If application site toxicity occurs, the application frequency can be reduced. Should severe irritation occur, application of drug can be temporarily discontinued for a few days until the symptoms subside. See CONTRAINDICATIONS: Pregnancy. 

Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry before covering with clothing. Because unaffected skin may become irritated, application of the gel to normal skin surrounding the lesions should be avoided. In addition, do not apply the gel near mucosal surfaces of the body. 

A response may be seen as soon as four weeks after initiation of therapy but most patients require longer application. With continued application, further benefit may be attained. The longest onset time for the first response among the responders was 392 days based on the Composite Assessment of Index Lesion Severity in the multicenter study. In clinical trials, bexarotene gel, 1% was applied for up to 172 weeks. 

Bexarotene gel, 1% should be continued as long as the patient is deriving benefit. 

Occlusive dressings should not be used with bexarotene gel, 1%. 

BEXAROTENE GEL, 1% IS A TOPICAL THERAPY AND IS NOT INTENDED FOR SYSTEMIC USE. BEXAROTENE GEL, 1% HAS NOT BEEN STUDIED IN COMBINATION WITH OTHER CTCL THERAPIES.
NEW MATERIAL:Polysaccharide YT.IIa. Properties: white powder. Structural saccharide: glucose and a very small amount of galactose. Bond style of structural saccharide:alpha bond. Specific rotatory power:[alpha]D<20>=+190+ or -9(C=0.48, H2O). Molecular weight: 8,000+ or -2,000 (gel filtration chromotography). Solubility: soluble in water and dilute aqueous solution of inorganic salt, insoluble in a hydrophobic organic solvent such as ether, etc. and hydrophilic organic solvent such as methanol, etc. Elemental analysis value: C 40+ or -3wt%, H 6+ or -3wt%, N zero. USE:An improver for cancerous symptoms. Inhibiting promoting action on decomposition of fats and oils of cancerous toxin having decomposition action on fats and oils, improving lipometabolism of cancerous patient and lack of appetite. PREPARATION:An extracted solution of root of a plant belonging to the genus angelica of the family Umbelliferae in an aqueous solvent is dialyzed to give a dialyzed filtrate, to which an equivalent amount of a saturated aqueous solution of ammonium sulfate is added, the precipitate is removed, further an equivalent amount of saturated aqueous solution of ammonium sulfate is added to it, and the prepared precipitate is desalted. It is dissolved in an aqueous solvent, subjected to ultrafiltration, a fraction having <=300,000mol.wt. is collected, it is subjected to gel filtration chromatography to give a fraction having 6,000-10,000 mol.wt., which is further purified to give polysaccharide YT-IIa.
A literature review reflects data on the mechanisms of pulmonary fibrosis after a novel coronavirus infection associated with the SARS-COV2 virus. Factors contributing to post-COVID lung remodeling are considered. According to the literature, in the mechanism of pulmonary fibrosis, during the course of the disease and during the recovery period, both direct viral damage and death of alveolocytes and endothelium, the development of a systemic inflammatory reaction due to inadequate secretion of cytokines, especially type 2, which are activators of the proliferation of fibroblasts and myofibroblasts, are important. The influence of angiogenesis disorders and vascular dysfunction on pneumofibrosis was noted. Attention is also paid to the relationship between the development of pulmonary fibrosis and abnormal activation of the renin-angiotensin-aldosterone system. In combination with the action of many factors, especially germinal ones, an imbalance between profibrogenic and antifibrogenic action develops and fibrosis occurs.
An observational cross-sectional study was conducted to examine multidimensional frailty and its potential impact on quality of life (QOL) in aging Hispanic people living with HIV (PLWH) and assess the extent to which HIV self-management moderates this association. The sample included 120 Hispanic PLWH aged 50 years and older (M = 59.11; SD = 7.04). The structural equation modeling analyses demonstrated that multidimensional frailty was significantly related to QOL in its two dimensions, physical and mental (p < .001). The relationship between multidimensional frailty and mental and physical QOL remained significant even after controlling for confounders (age and gender). The moderator analyses indicated no statistically significant moderator effect of HIV self-management on multidimensional frailty and mental or physical QOL. These study results have practical implications that highlight the need for early screening for frailty with a multidimensional focus. Age-appropriate and culturally tailored interventions to prevent or mitigate multidimensional frailty may improve QOL.
<P>PROBLEM TO BE SOLVED: To obtain an oxidation hair dye composition having excellent dyeability and fastness to shampooing.  <P>SOLUTION: This oxidation dye composition having the excellent dyeability and fastness to shampooing can be obtained by formulating an amino acid or its salt in an oxidation hair dye-containing p-phenylenediamine. The amino acid used herein is not especially limited if the amino acid is used. The amino acid preferably has sulfur and includes, e.g. cystine, cysteine and methionine, more preferably cysteine. When monoethanolamine is formulated, there has been disadvantages such as poor dyeability and fastness to shampooing. However, by this invention, merchandise satisfactory to the dyeability and fastness to shampooing can be provided without being annoyed with an irritant order.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Store NARCAN Nasal Spray in the blister and cartons provided.

Store below 77°F (25°C). Excursions permitted up to 104°F (40°C). Do not freeze or expose to excessive heat above 104°F (40°C). Protect from light.

NARCAN Nasal Spray freezes at temperatures below 5°F (-15°C). If this happens, the device will not spray. If NARCAN Nasal Spray is frozen and is needed in an emergency, do NOT wait for NARCAN Nasal Spray to thaw. Get emergency medical help right away. However, NARCAN Nasal Spray may be thawed by allowing it to sit at room temperature for 15 minutes, and it may still be used if it has been thawed after being previously frozen.
FIELD: cosmetic industry. SUBSTANCE: composition comprises hydrolyzed protein containing many anionic amino acids and bivalent cationic compounds also being anionic components of hydrolyzed protein are able to bind with hair by cationic bridges effectively. Composition can comprise additionally vitamins that enhance protective properties. Composition provides protection against damage associated with effects of environment and chemical reagents. EFFECT: improved and enhanced properties of composition. 14 cl, 6 tbl, 13 ex
To assess the correlations among the physical functional performance, muscle strength, respiratory muscle strength and the ventilator weaning rate. Investigators use the DEMMI and FSS-ICU to evaluation the physical functional performance. And MRC score and hand dynamometer to record the muscle strength. The weaning parameters include Pi, PE, RSI,minute ventilation, tidal volume and cuff leak will be recorded. After the participant enters the Respiration Care Center, Doctor and physical therapist evaluate the consciousness and meet the inclusion criteria and the participant will received the first evaluation. The second evaluation will be held before the ventilator weaning timing.